RedHill Biopharma ( (RDHL) ) has provided an announcement.
RedHill Biopharma announced its intention to submit a UK Marketing Authorisation Application for Talicia, an FDA-approved therapy for H. pylori infection, using the MHRA’s fast-track approval process. Talicia, already approved in the UAE, is a leading therapy in the U.S. and could significantly impact the billion-dollar H. pylori market, affecting a large portion of the global population. The potential UK approval, expected by Q4 2025, may also facilitate further international market entries.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology. The company promotes Talicia®, an FDA-approved drug for the treatment of Helicobacter pylori (H. pylori) infection in adults, and is involved in several late-stage clinical development programs targeting various diseases.
YTD Price Performance: -52.97%
Average Trading Volume: 71,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.26M
For an in-depth examination of RDHL stock, go to TipRanks’ Stock Analysis page.